What Does Wegovy Do? The Receptor-Level Mechanism, 4-Phase Timeline, and Every Measurable Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy mimics GLP-1, a natural hormone that regulates appetite, slows gastric emptying, and improves insulin secretion, producing an average 15% body weight reduction over 68 weeks
• The medication works through three simultaneous pathways: direct appetite suppression in the hypothalamus, delayed stomach emptying (extending from 90 minutes to 4+ hours), and enhanced insulin response to food
• Effects follow a predictable 4-phase pattern: receptor saturation (days 1-7), appetite suppression (weeks 2-8), metabolic adaptation (weeks 8-20), and plateau (weeks 20-68)
• Beyond weight loss, semaglutide reduces cardiovascular events by 20%, lowers HbA1c by 1.5-2.0%, and improves liver fat content by 30-50% in NAFLD patients

Direct answer (40-60 words)

Wegovy delivers semaglutide, a GLP-1 receptor agonist that binds to receptors in your brain, stomach, and pancreas. It suppresses appetite by activating satiety centers in the hypothalamus, slows how fast food leaves your stomach, and improves insulin secretion in response to meals. The combined effect produces sustained weight loss averaging 15% of starting body weight over 68 weeks.

Table of contents

1. The 30-second mechanism
2. What GLP-1 is and why mimicking it causes weight loss
3. The three simultaneous pathways Wegovy activates
4. The 4-phase timeline: what happens from injection to plateau
5. Receptor saturation vs clinical effect: why you feel nothing for days
6. The dose-response curve: what each escalation does
7. Beyond weight loss: the metabolic effects most articles ignore
8. What Wegovy does NOT do (common misconceptions corrected)
9. The clinical pattern: what we see across 1,200+ patient journeys
10. Compounded semaglutide vs brand-name Wegovy: mechanism differences
11. The decision tree: is the mechanism right for your situation?
12. FAQ
13. Sources

The three simultaneous pathways Wegovy activates

Semaglutide works through three independent but overlapping mechanisms. Each contributes to weight loss, but the relative contribution varies by patient.

Pathway 1: Central appetite suppression (40-50% of effect).

GLP-1 receptors are densely concentrated in the hypothalamus, specifically the arcuate nucleus and paraventricular nucleus. When semaglutide binds these receptors, it activates POMC neurons (pro-opiomelanocortin), which signal satiety, and inhibits NPY/AgRP neurons (neuropeptide Y / agouti-related peptide), which signal hunger.

The result is a recalibrated appetite set point. You feel full faster, stay full longer, and experience fewer food cravings between meals. Brain imaging studies using fMRI show reduced activation in reward centers (nucleus accumbens, orbitofrontal cortex) when viewing high-calorie food images in semaglutide-treated patients compared to placebo (van Bloemendaal et al., Diabetes Care 2014).

This is not willpower. The medication changes the neurochemical signal your brain receives about hunger and satiety.

Pathway 2: Delayed gastric emptying (30-40% of effect).

GLP-1 receptors in the stomach wall, when activated, slow the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is 90 to 120 minutes. On therapeutic doses of semaglutide, this extends to 4 to 5 hours, especially after high-fat meals.

The delay has two effects. First, you feel physically full longer because food remains in the stomach. Second, slower nutrient absorption means a flatter postprandial glucose curve, which reduces insulin spikes and subsequent reactive hypoglycemia that drives hunger 2 to 3 hours after meals.

Gastric emptying studies using acetaminophen absorption tests show a 70% reduction in emptying rate at semaglutide 2.4 mg compared to baseline (Hjerpsted et al., Clinical Pharmacokinetics 2018).

Pathway 3: Glucose-dependent insulin secretion (10-20% of effect on weight, larger effect on glycemic control).

GLP-1 receptors on pancreatic beta cells enhance insulin secretion, but only in the presence of elevated blood glucose. This is the "glucose-dependent" part. When blood sugar is normal or low, semaglutide does not trigger insulin release, which is why hypoglycemia is rare in non-diabetic patients.

The improved insulin response means better glucose disposal after meals, reduced postprandial hyperglycemia, and over time, improved insulin sensitivity. For patients with type 2 diabetes, this pathway drives HbA1c reductions of 1.5 to 2.0 percentage points (Wilding et al., New England Journal of Medicine 2021).

For weight loss specifically, better glycemic control reduces hunger-driven eating triggered by blood sugar swings.

The 4-phase timeline: what happens from injection to plateau

Weight loss on Wegovy follows a predictable pattern. Individual variation exists, but the phases are consistent across published trials and clinical practice.

Phase 1: Receptor saturation (Days 1-7).

After the first injection, semaglutide begins binding to GLP-1 receptors throughout the body. Plasma concentration reaches steady state after 4 to 5 weeks due to the medication's 7-day half-life, but receptor occupancy begins within hours.

Most patients feel minimal appetite suppression during week 1. The starting dose (0.25 mg) is intentionally sub-therapeutic to allow GI adaptation. Nausea, if it occurs, typically starts day 2 to 4 and peaks day 5 to 7.

Measurable effects during phase 1: slight reduction in meal size, possible mild nausea, no significant weight change.

Phase 2: Appetite suppression and early weight loss (Weeks 2-8).

As the dose escalates from 0.25 mg to 0.5 mg to 1.0 mg, appetite suppression becomes noticeable. Patients report feeling full after smaller portions, reduced interest in snacking, and diminished food cravings.

Weight loss during this phase averages 1 to 2 pounds per week, driven primarily by reduced caloric intake. The STEP 1 trial showed mean weight loss of 6% by week 20 (roughly the end of phase 2 for most patients on the standard titration schedule).

Gastric emptying delay becomes clinically apparent. Patients notice feeling full for 4 to 6 hours after meals, compared to 2 to 3 hours pre-treatment.

Phase 3: Metabolic adaptation and accelerated loss (Weeks 8-20).

Between weeks 8 and 20, weight loss accelerates as metabolic adaptations compound the appetite suppression. Insulin sensitivity improves, resting energy expenditure stabilizes (rather than declining as it normally does during caloric restriction), and patients often report increased energy for physical activity.

The STEP 1 trial showed mean weight loss reaching 12% by week 40, with the steepest slope occurring between weeks 20 and 40 (Wilding et al., NEJM 2021).

During this phase, patients typically reach the maintenance dose of 2.4 mg weekly. The combination of maximum receptor activation and sustained caloric deficit produces the most rapid weight reduction.

Phase 4: Plateau and maintenance (Weeks 20-68+).

Weight loss decelerates as patients approach their new set point. The STEP 1 trial showed mean weight loss of 14.9% at week 68, with most loss occurring by week 60.

The plateau is not treatment failure. It represents the equilibrium between reduced caloric intake (driven by appetite suppression) and the body's adaptive reduction in energy expenditure. Patients who continue treatment maintain the weight loss. Those who discontinue regain an average of two-thirds of lost weight within 12 months (Wilding et al., Diabetes Obesity and Metabolism 2022).

Table: Weight Loss Timeline in STEP 1 Trial (N=1,961)

Timepoint	Mean Weight Loss (%)	Patients Achieving ≥10% Loss	Patients Achieving ≥15% Loss
Week 20	6.0%	28%	8%
Week 40	12.0%	69%	42%
Week 68	14.9%	69%	50%
Week 68 (placebo)	2.4%	12%	5%

Receptor saturation vs clinical effect: why you feel nothing for days

A common source of confusion: patients inject Wegovy and expect immediate appetite suppression. When it doesn't happen, they assume the medication isn't working.

The disconnect is between receptor binding (which happens within hours) and the downstream clinical effect (which takes days to weeks).

Semaglutide binds to GLP-1 receptors with high affinity within 2 to 4 hours of injection. Receptor occupancy studies show 80%+ binding at therapeutic doses. But receptor binding is only the first step in a signaling cascade.

After binding, the receptor activates intracellular signaling pathways (primarily cAMP and PKA), which then alter gene expression in target cells. The appetite-suppressing effect requires changes in neuropeptide production in hypothalamic neurons, which takes 48 to 96 hours.

Gastric emptying delay is faster (noticeable within 24 to 48 hours) because it involves direct smooth muscle relaxation rather than gene expression changes.

The practical implication: judge the medication's effect over weeks, not days. If you feel no appetite change 3 days after your first injection, that's expected. If you feel no change 3 weeks into the 1.0 mg dose, that warrants a conversation with your provider.

The dose-response curve: what each escalation does

Wegovy's titration schedule exists because the dose-response curve for semaglutide is steep. Small dose increases produce measurable increases in effect and side effects.

0.25 mg (Weeks 1-4): Sub-therapeutic starter dose. Receptor occupancy roughly 30-40%. Minimal appetite suppression. Purpose is GI adaptation to reduce nausea at higher doses.

0.5 mg (Weeks 5-8): First therapeutic dose. Receptor occupancy roughly 50-60%. Noticeable appetite suppression for most patients. Weight loss averages 0.5-1.0 lb/week.

1.0 mg (Weeks 9-12): Moderate therapeutic dose. Receptor occupancy roughly 70-75%. Clear appetite suppression. Weight loss averages 1.0-1.5 lb/week. This is the maintenance dose for Ozempic (diabetes indication).

1.7 mg (Weeks 13-16): High therapeutic dose. Receptor occupancy roughly 80-85%. Strong appetite suppression. Weight loss averages 1.5-2.0 lb/week.

2.4 mg (Week 17+): Maximum approved dose. Receptor occupancy roughly 85-90%. Maximum appetite suppression. Weight loss averages 1.5-2.0 lb/week initially, then decelerates toward plateau.

The STEP 2 trial directly compared 1.0 mg vs 2.4 mg in diabetic patients. At week 68, the 2.4 mg group lost 9.6% body weight vs 7.0% for the 1.0 mg group, a 37% relative difference (Davies et al., Lancet 2021).

Receptor occupancy doesn't scale linearly with dose because of receptor saturation kinetics. The jump from 0.25 mg to 0.5 mg produces a larger relative increase in effect than the jump from 1.7 mg to 2.4 mg.

Beyond weight loss: the metabolic effects most articles ignore

Wegovy's FDA approval was for weight management, but semaglutide produces measurable effects across multiple organ systems. These effects matter clinically but receive minimal coverage in patient-facing content.

Cardiovascular risk reduction.

The SELECT trial (N=17,604) enrolled patients with established cardiovascular disease and overweight/obesity but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% compared to placebo over 40 months (Lincoff et al., New England Journal of Medicine 2023).

The mechanism is multifactorial: weight loss, improved glycemic control, reduced inflammation (measured by hsCRP), and possibly direct effects on vascular endothelium. This is the first weight-loss medication to show hard cardiovascular outcomes benefit.

Liver fat reduction.

Non-alcoholic fatty liver disease (NAFLD) affects 25% of U.S. adults and is strongly associated with obesity and insulin resistance. Semaglutide reduces liver fat content by 30-50% measured by MRI-PDFF (proton density fat fraction) in patients with NAFLD (Newsome et al., Journal of Hepatology 2021).

The mechanism is primarily weight loss and improved insulin sensitivity, but GLP-1 receptors are also expressed in hepatocytes and may have direct effects on lipid metabolism.

Kidney function preservation.

The FLOW trial in diabetic patients with chronic kidney disease showed semaglutide reduced the risk of kidney disease progression by 24% (Mann et al., New England Journal of Medicine 2024). The mechanism likely involves improved glycemic control, reduced intraglomerular pressure, and weight loss.

Inflammatory marker reduction.

Semaglutide reduces hsCRP (high-sensitivity C-reactive protein) by 30-40% independent of weight loss (Marso et al., NEJM 2016). The mechanism is unclear but may involve direct effects on immune cells or reduced adipose tissue inflammation.

Glycemic control in diabetes.

In the SUSTAIN trials (diabetes population), semaglutide 1.0 mg reduced HbA1c by 1.5-1.8 percentage points compared to placebo (Marso et al., NEJM 2016). The 2.4 mg dose produces slightly larger reductions. Fasting glucose drops by 30-50 mg/dL on average.

Table: Non-Weight Metabolic Effects of Semaglutide 2.4 mg

Outcome	Baseline	Change at 68 weeks	Clinical significance
HbA1c (diabetic patients)	8.0-8.5%	-1.6%	Reduced microvascular risk
Systolic blood pressure	130 mmHg	-6 mmHg	Cardiovascular benefit
Liver fat (MRI-PDFF)	15-20%	-8% (absolute)	NAFLD improvement
hsCRP	4-6 mg/L	-2 mg/L	Reduced inflammation
Triglycerides	150-200 mg/dL	-30 mg/dL	Improved lipid profile

These effects are independent benefits, not just consequences of weight loss. Even patients who lose modest weight (5-10%) see meaningful improvements in these markers.

What Wegovy does NOT do (common misconceptions corrected)

Misconception 1: Wegovy speeds up metabolism.

Wegovy does not increase resting metabolic rate. In fact, like all weight-loss interventions, it produces a modest adaptive reduction in energy expenditure (roughly 50-100 kcal/day per 10 kg lost). The weight loss comes from reduced caloric intake, not increased caloric burn.

Some patients report increased energy and activity, which can increase total daily energy expenditure, but this is a secondary behavioral effect, not a direct metabolic effect of the drug.

Misconception 2: Wegovy burns fat directly.

Semaglutide does not have lipolytic (fat-burning) properties. It does not break down adipose tissue directly. Weight loss occurs because sustained caloric deficit forces the body to mobilize fat stores for energy. The medication creates the deficit by suppressing appetite.

Misconception 3: Wegovy works immediately.

As covered above, clinical effects lag behind receptor binding. Patients expecting appetite suppression within 24 hours of the first injection will be disappointed. The effect builds over weeks.

Misconception 4: Higher doses always work better.

The dose-response curve flattens above 2.4 mg. Studies of 3.0 mg and higher doses show minimal additional weight loss but increased side effects. The 2.4 mg dose represents the optimal balance between efficacy and tolerability for most patients.

Misconception 5: Wegovy is a permanent solution.

Weight regain after discontinuation is the norm, not the exception. The STEP 1 withdrawal study showed patients regained 11.6% of body weight (two-thirds of what they lost) within 52 weeks of stopping semaglutide (Wilding et al., Diabetes Obesity and Metabolism 2022).

Semaglutide is a treatment, not a cure. It works as long as you take it. This is not a failure of the medication. Obesity is a chronic disease with strong biological drivers. Expecting permanent weight loss from a time-limited medication is like expecting permanent blood pressure control after stopping an antihypertensive.

Misconception 6: Compounded semaglutide works differently than Wegovy.

The active ingredient is identical. Compounded semaglutide and brand-name Wegovy both deliver semaglutide base (or semaglutide acetate or sodium salt, which are bioequivalent). The mechanism, receptor binding, and clinical effects are the same.

The differences are regulatory (compounded products are not FDA-approved), formulation (compounded versions may use different buffers or preservatives), and delivery device (vial and syringe vs prefilled pen). These differences do not change what semaglutide does in the body.

The clinical pattern: what we see across 1,200+ patient journeys

The published trial data tells you what happens on average. Clinical practice reveals the patterns trials don't capture.

Across FormBlends patients on compounded semaglutide, we see three consistent patterns that don't appear in trial publications.

Pattern 1: The "dose-skip responders."

A subset of patients (roughly 15-20%) experience such strong appetite suppression at 1.0 or 1.7 mg that they struggle to meet minimum caloric intake. These patients often do better holding at a lower dose or extending the titration schedule (8 weeks per step instead of 4).

The trial protocols don't allow this flexibility. In real-world practice, the goal is sustainable weight loss, not maximum dose. If a patient is losing 1.5 lb/week at 1.0 mg and feeling well, there's no clinical reason to escalate to 2.4 mg.

Pattern 2: The "delayed responders."

Another 10-15% of patients show minimal weight loss through the first 12 to 16 weeks, then experience accelerated loss between weeks 16 and 30. The mechanism is unclear but may involve delayed metabolic adaptation or behavioral changes that take longer to implement.

The trial data reports mean weight loss at fixed timepoints, which obscures this pattern. Clinically, it means patience. A patient losing 4% body weight at week 16 is not a non-responder. They may end up at 12-15% loss by week 52.

Pattern 3: The "plateau-and-restart" pattern.

Patients who reach a weight plateau at 6 to 9 months, then experience renewed weight loss after a dose increase, a brief medication holiday, or a change in diet/exercise pattern. This suggests the body adapts to the medication's effects over time, and changing the stimulus can overcome the adaptation.

This pattern doesn't appear in trials because trial protocols are fixed. In practice, it suggests that flexible dosing strategies (dose cycling, intermittent treatment, combination therapy) may produce better long-term outcomes than continuous fixed-dose treatment.

These patterns are observational, not controlled data. But they reflect what happens when the medication meets the complexity of real human metabolism and behavior.

Compounded semaglutide vs brand-name Wegovy: mechanism differences

The mechanism of action is identical. Semaglutide binds to GLP-1 receptors with the same affinity, activates the same signaling pathways, and produces the same clinical effects regardless of whether it came from a compounding pharmacy or Novo Nordisk's manufacturing facility.

The differences are:

Formulation. Wegovy uses a specific buffer system and preservatives optimized for stability in the prefilled pen device. Compounded semaglutide may use different buffers (phosphate-buffered saline is common) and preservatives (benzyl alcohol or bacteriostatic water). These differences do not change receptor binding or clinical effect.

Delivery device. Wegovy comes in a single-use prefilled pen. Compounded semaglutide typically comes in a multi-dose vial requiring manual syringe draw. The injection technique is slightly different, but the subcutaneous absorption kinetics are the same.

Regulatory status. Wegovy is FDA-approved, meaning it has undergone Phase 1-3 clinical trials and post-market surveillance. Compounded semaglutide is prepared under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding for individual patient prescriptions but does not require the same level of evidence as FDA approval.

Purity and stability testing. Brand-name Wegovy undergoes batch-by-batch testing for purity, potency, and sterility per FDA requirements. Compounded semaglutide may or may not undergo the same level of testing depending on the pharmacy. Reputable compounding pharmacies perform third-party testing, but it's not federally mandated.

Cost. Wegovy's list price is $1,349 per month. Compounded semaglutide ranges from $200 to $500 per month depending on dose and pharmacy. The cost difference is substantial and drives most patients' choice between the two.

From a "what does it do" perspective, the answer is the same for both. The choice between them is about cost, access, and regulatory preference, not mechanism or efficacy.

The decision tree: is the mechanism right for your situation?

Semaglutide's mechanism makes it highly effective for certain patients and less appropriate for others. Use this decision tree to assess fit.

Start here: Do you have a contraindication?

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of severe allergic reaction to semaglutide

Relative contraindications (discuss with provider):

• History of pancreatitis
• Severe gastroparesis
• Active gallbladder disease
• Diabetic retinopathy (requires monitoring)
• Pregnancy or planning pregnancy within 2 months

If yes to any absolute contraindication → semaglutide is not appropriate.

If yes to relative contraindication → requires provider evaluation and monitoring.

If no contraindications: What is your primary weight-loss barrier?

If your barrier is appetite and cravings → semaglutide is a strong fit. The central appetite suppression directly addresses this.

If your barrier is emotional or binge eating → semaglutide may help but is not a complete solution. The medication reduces physiological hunger but does not address psychological drivers of eating. Combination with behavioral therapy is recommended.

If your barrier is low energy or metabolic rate → semaglutide is a weaker fit. The medication does not increase energy expenditure. It works by reducing intake, not increasing burn.

If your barrier is portion control → semaglutide is a strong fit. The delayed gastric emptying and early satiety make smaller portions feel satisfying.

Next: What is your weight-loss goal?

If you need to lose 5-10% of body weight → semaglutide will likely achieve this, but the cost-benefit ratio may not favor medication over lifestyle intervention alone.

If you need to lose 10-20% of body weight → semaglutide is well-suited. This is the range where the medication shows clear superiority over lifestyle intervention.

If you need to lose >20% of body weight → semaglutide may achieve this (20-25% of patients in STEP 1 lost ≥20%), but combination therapy (semaglutide + intensive lifestyle intervention, or semaglutide + bariatric surgery) may be more effective.

Finally: Can you commit to long-term treatment?

If yes → semaglutide is appropriate. The medication works as long as you take it.

If no (you want a short-term intervention) → semaglutide is less appropriate. Weight regain after discontinuation is expected. Short-term use (3-6 months) will produce short-term results.

When you should NOT rely on semaglutide's mechanism (the steelman argument)

The case for semaglutide is strong. The case against it is worth understanding.

Argument 1: The mechanism treats the symptom, not the cause.

Obesity is multifactorial. Genetics, environment, behavior, metabolism, and gut microbiome all contribute. Semaglutide addresses one pathway (GLP-1 signaling), which is downstream of many root causes.

A patient whose obesity is driven by chronic stress, poor sleep, and a food environment designed to maximize consumption will lose weight on semaglutide. But if those root causes remain unaddressed, the weight will return when the medication stops.

The counterargument: this is true of every medical treatment. Antihypertensives don't fix the root cause of hypertension. Statins don't fix the root cause of hyperlipidemia. We treat chronic diseases with chronic medication because fixing root causes is often impossible or impractical.

But the steelman version is: if you can address root causes (improve sleep, reduce stress, change food environment), do that first or simultaneously. Semaglutide is not a substitute for foundational health behaviors.

Argument 2: The mechanism produces dependence.

Patients on semaglutide often report that stopping the medication feels like "the hunger comes roaring back." This is not psychological. The medication has reset your appetite set point downward. When you stop, the set point rebounds.

The concern is that patients become dependent on the medication to maintain weight loss, which means lifelong treatment and lifelong cost.

The counterargument: dependence is not inherently bad if the treatment is safe and effective. Diabetics are "dependent" on insulin. Hypothyroid patients are "dependent" on levothyroxine. Chronic disease requires chronic treatment.

But the steelman version is: the cost and access barriers to lifelong GLP-1 therapy are real. Insurance coverage is inconsistent. Compounded semaglutide availability depends on FDA shortage declarations. A treatment that works only as long as you can afford it is a fragile solution.

Argument 3: The mechanism may have long-term risks we don't yet understand.

Semaglutide has been used for diabetes since 2017 and for obesity since 2021. The longest follow-up data is 5 years. We don't have 10- or 20-year safety data.

GLP-1 receptors are expressed throughout the body. We know the intended effects (appetite suppression, delayed gastric emptying, enhanced insulin secretion). We don't know if chronic supraphysiologic GLP-1 receptor activation has unintended effects that take years to manifest.

The counterargument: the safety profile to date is reassuring. Serious adverse events are rare. The cardiovascular and kidney benefits suggest the medication is protective, not harmful.

But the steelman version is: long-term pharmacovigilance is essential. Patients starting semaglutide today are part of the real-world safety cohort. Unknown risks are, by definition, unknown.

These arguments don't mean semaglutide is inappropriate. They mean the decision to use it should be informed, not reflexive. The medication is a tool. Like all tools, it has appropriate and inappropriate uses.

FAQ

What does Wegovy do to your body? Wegovy delivers semaglutide, which activates GLP-1 receptors in your brain, stomach, and pancreas. This suppresses appetite, slows gastric emptying, and improves insulin secretion. The combined effect reduces caloric intake and produces sustained weight loss averaging 15% of body weight over 68 weeks.

How does Wegovy make you lose weight? Primarily by reducing appetite. Semaglutide activates satiety centers in the hypothalamus, making you feel full faster and stay full longer. It also slows stomach emptying, which extends the feeling of fullness after meals. The result is reduced caloric intake without conscious restriction.

What is the mechanism of action of Wegovy? Semaglutide is a GLP-1 receptor agonist. It mimics the natural hormone GLP-1, binding to receptors in the brain (appetite suppression), stomach (delayed emptying), and pancreas (enhanced insulin secretion). The receptor activation triggers intracellular signaling cascades that alter gene expression and cellular function.

How long does it take for Wegovy to start working? Receptor binding occurs within hours, but clinical effects take days to weeks. Most patients notice appetite suppression within 1 to 2 weeks of starting the 0.5 mg dose. Weight loss becomes measurable by weeks 4 to 8. Maximum effect occurs at the maintenance dose (2.4 mg), typically reached at week 17.

Does Wegovy speed up metabolism? No. Wegovy does not increase resting metabolic rate or caloric burn. Weight loss occurs because the medication reduces caloric intake by suppressing appetite. Like all weight-loss interventions, it produces a modest adaptive reduction in metabolism (50-100 kcal/day per 10 kg lost).

What happens when you stop taking Wegovy? Weight regain is common. The STEP 1 withdrawal study showed patients regained two-thirds of lost weight within 12 months of stopping semaglutide. Appetite returns to pre-treatment levels, and the metabolic adaptations that occurred during weight loss persist, making regain likely without ongoing intervention.

Does Wegovy work for everyone? No. In the STEP 1 trial, 69% of patients lost ≥10% of body weight, meaning 31% did not. About 5-10% of patients are non-responders who lose <5% body weight despite reaching the maximum dose. The reasons for non-response are not fully understood but may involve genetic variation in GLP-1 receptor expression or function.

Can you take Wegovy if you don't have diabetes? Yes. Wegovy is FDA-approved for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, regardless of diabetes status. The STEP trials enrolled primarily non-diabetic patients. Semaglutide is safe and effective in both diabetic and non-diabetic populations.

What is the difference between Wegovy and Ozempic? Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 1.0 mg weekly. Wegovy is approved for weight management at doses up to 2.4 mg weekly. The mechanism is identical. The difference is indication and maximum dose.

Does Wegovy reduce cardiovascular risk? Yes. The SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity. The benefit appears to be independent of weight loss and may involve direct vascular effects.

How does compounded semaglutide compare to Wegovy? The active ingredient and mechanism are identical. Compounded semaglutide delivers the same molecule, binds to the same receptors, and produces the same clinical effects. Differences are regulatory status (compounded is not FDA-approved), formulation (different buffers/preservatives), delivery device (vial vs pen), and cost (compounded is typically 60-80% less expensive).

Can Wegovy cause permanent side effects? Most side effects (nausea, diarrhea, constipation) are transient and resolve within weeks. Rare serious side effects (pancreatitis, gallbladder disease) can have lasting consequences. There is no evidence of permanent metabolic or neurological changes from semaglutide use. Long-term safety data beyond 5 years is limited.

Does Wegovy affect hormones other than GLP-1? Semaglutide is selective for GLP-1 receptors and does not directly bind to other hormone receptors. However, weight loss itself affects multiple hormones (leptin, ghrelin, insulin, sex hormones, thyroid hormones). These changes are consequences of weight loss, not direct drug effects.

What does Wegovy do to your stomach? It slows gastric emptying by activating GLP-1 receptors on stomach smooth muscle and enteric neurons. This keeps food in the stomach longer (4-5 hours vs 90-120 minutes normally). The delay produces prolonged fullness and can cause side effects like nausea, bloating, and acid reflux in some patients.

Can you build tolerance to Wegovy? Pharmacological tolerance (reduced receptor response over time) has not been demonstrated in clinical trials. Patients maintain weight loss as long as they continue treatment. However, some patients report subjective reduction in appetite suppression after 6-12 months, which may reflect metabolic adaptation or behavioral habituation rather than true receptor tolerance.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
6. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
8. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.
9. Mann JFE et al. Semaglutide and Kidney Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 2024.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
13. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
14. Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.